$GH News

Wolfe Research Assumes Guardant Health at Outperform, Announces Price Target of $150

Evercore ISI Group Upgrades Guardant Health to Outperform, Raises Price Target to $160

Testing & Diagnostics Services Stocks Q1 Earnings: Guardant Health (NASDAQ:GH) Firing on All Cylinders

Guardant Health To Present 38 Abstracts, As Well As One Oral Presentation In Partnership With Pfizer, Showcasing Advances In Methylation-Based Tumor Classification And Liquid Biopsy Technology At ASCO Annual Meeting 2026

BTIG Maintains Buy on Guardant Health, Raises Price Target to $160

American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

Guardant Health Says Its FDA-Approved Shield Blood Test Is Now Included In Updated American Cancer Society Colorectal Cancer Screening Guidelines

BTIG Maintains Buy on Guardant Health, Raises Price Target to $155

A Look At Guardant Health’s Valuation After Its Recent Share Price Surge

Guardant Health (GH) Is Up 25.3% After FDA Clears First Genomic‑Epigenomic Liquid Biopsy Panel – Has The Bull Case Changed?

Guardant wins FDA approval for updated liquid biopsy

Guardant Health Leaps On A Major Win In Cancer Detection; Will Shares Break Out?

Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test

FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint

Guardant Health Announces FDA Approval Of The Company's Liquid CDx To Advance Blood-Based Comprehensive Genomic Testing

Why Guardant Health (GH) Stock Is Down Today

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The Top 5 Analyst Questions From Guardant Health’s Q1 Earnings Call

Guardant Health (GH) Q1 Revenue Jumps 48% to $301.7M on Strong Screening Growth

Guardant Health: Reveal And Shield Driving The Next Growth Phase